Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/20/18
End: 03/07/23
Due: 03/07/24
Phase: N/A
Priority: Normal
Start: 01/08/19
End: 02/15/21
Due: 02/15/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer | NCT03658772 | Arrys Therapeutics | user2@example.com | None | 2018-09-20 | 2023-03-07 | 2024-03-07 | - | - | 2025-07-14 |
| Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma | NCT03696212 | Arrys Therapeutics | user2@example.com | None | 2019-01-08 | 2021-02-15 | 2022-02-15 | - | - | 2025-07-14 |